Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. - Wikidata - awgldk - TriplyDB

Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma.

Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma.

http://www.wikidata.org/entity/Q37304132

about

Nerve growth factor: role in growth, differentiation and controlling cancer cell development Current perspective of neuroprotection and glaucoma Nerve Growth Factor: A Focus on Neuroscience and Therapy Neuroprotection, Growth Factors and BDNF-TrkB Signalling in Retinal Degeneration Exploring Serum Levels of Brain Derived Neurotrophic Factor and Nerve Growth Factor Across Glaucoma Stages Functional Characterization of Human ProNGF and NGF Mutants: Identification of NGF P61SR100E as a "Painless" Lead Investigational Candidate for Therapeutic Applications Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial The multiple life of nerve growth factor: tribute to rita levi-montalcini (1909-2012)Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma.Glaucoma: genes, phenotypes, and new directions for therapy.Intranasal nerve growth factor bypasses the blood-brain barrier and affects spinal cord neurons in spinal cord injury.Vitamin D3 deficiency differentially affects functional and disease outcomes in the G93A mouse model of amyotrophic lateral sclerosis.The nerve growth factor signaling and its potential as therapeutic target for glaucoma Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement Dry eye disease: A review of diagnostic approaches and treatments Efficacy and tolerability of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials.Rationale for the use of multifunctional drugs as neuroprotective agents for glaucoma.Effect of purified murine NGF on isolated photoreceptors of a rodent developing retinitis pigmentosa.Efficacy and safety of nerve growth factor for the treatment of neurological diseases: a meta-analysis of 64 randomized controlled trials involving 6,297 patients Enhanced bioavailability of nerve growth factor with phytantriol lipid-based crystalline nanoparticles in cochlea The novel synthetic microneurotrophin BNN27 protects mature oligodendrocytes against cuprizone-induced death, through the NGF receptor TrkA.Nerve growth factor: from the early discoveries to the potential clinical use On Rita Levi-Montalcini.Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.Hypoxic-Preconditioned Bone Marrow Stem Cell Medium Significantly Improves Outcome After Retinal Ischemia in Rats.Intracerebroventricular administration of nerve growth factor induces gliogenesis in sensory ganglia, dorsal root, and within the dorsal root entry zone.Mechanisms of retinal ganglion cell injury and defense in glaucoma.Topical administration of adrenergic receptor pharmaceutics and nerve growth factor.Current and emerging medical therapies in the treatment of glaucoma.Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy.Neuroprotection in diabetic retinopathy.Challenges in the development of glaucoma neuroprotection therapy.The cellular mechanisms of dry eye: from pathogenesis to treatment.Nerve growth factor: basic studies and possible therapeutic applications.Critical assessment of implantable drug delivery devices in glaucoma management.Nerve growth factor modulation of retinal ganglion cell physiology.Neurotrophin family members as neuroprotectants in retinal degenerations.Neuroprotective therapies for glaucoma.Biochemical changes and treatment in glaucoma.Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

P2860

Q26738684-4A02258E-E3DE-4ADA-9DE4-4133E2CDEBE8 Q26774852-FDBCBF89-5166-40BB-8AFC-498BD7D57DD0 Q26786398-2B28647A-15B7-47DA-A4AD-5622F082D909 Q28069477-CDB17365-419B-4293-88E0-5449DB45A3AC Q28468376-0A972991-1753-486F-AA76-8DB00ECA6907 Q28548019-0514E497-12D3-4418-9706-CC258924D24B Q33646680-52E6938B-5E94-4BE2-B1E6-7FE2B2A74E20 Q33974451-9252CA44-B479-4233-9878-B96773F11B4A Q34007825-DE974D63-68FC-4D7C-A109-0E6C535F8222 Q34090204-10E78EE5-9A60-484A-A024-33DD776E2FA6 Q34096327-D1D853A6-6436-4DB4-BFEF-E02819A95F80 Q34117516-940FD672-B879-40D8-B977-A38C09870C23 Q34182180-43DB1984-516D-4C9C-A841-AE89DFF09106 Q34255732-7EAC9D1F-9BEA-4E20-8F03-59A3219FBCFB Q34273384-22444CB5-8977-4334-B208-CB4D3184813A Q35071041-D63773EA-8C41-4069-90E4-4D93A1452DDC Q35157723-2D442D56-A728-42CB-9C6B-9088192EA3B3 Q35512477-CD924F2B-819E-4966-8CAA-C9E0D4566715 Q35673799-51486C25-31F1-4CD4-B8A0-D5533DDBE6C1 Q36265255-7D73662D-A1B4-44A6-A215-FFE8C329EE7E Q36388390-60699D84-B093-4534-A5F9-2CE54B2E006E Q36526946-FF5A827A-27B6-430F-9566-1D2BBC082F6B Q36660433-FAF8FB9C-ED8D-4BDE-A7DD-36CF529069F6 Q36771546-271922A3-30FE-46CD-A697-C1CD1A8CF29E Q37126430-CC7C722D-D094-4A71-88ED-BC556D704539 Q37677264-31469A7B-BF6E-4FB6-AE49-66BFFEA9C3B9 Q37731595-BB11905C-A850-49C7-86D4-005CC6964B19 Q37776419-D69EA8A7-19D3-4CB9-ADEB-FA312CEE4F28 Q37853195-F9CB1793-AF85-4186-92E4-EE145F30A79C Q37968179-418F14D3-99C5-4445-A740-74C5D6DB5D67 Q38009713-5EBDE4DB-1E92-4A51-AE85-FAC1E586F9FE Q38087849-CC3765BF-4BAE-43F2-B28D-420CBE6E2318 Q38108573-B50B973C-B153-4A58-9B8C-A7F617A21E19 Q38115344-8F296FB9-5E61-46B7-B49C-DF79EE8C1996 Q38143069-F84D7866-A395-4E83-97AE-A5C0B2B3DCEB Q38185629-AC665CB6-0C37-426E-9936-7750E4EA80E7 Q38269424-5EC2B41B-5835-4970-9252-E0F33DBA89E7 Q38384978-ED4481B4-90C4-4E90-AE9A-1E03C6CF0EA1 Q38443580-D9B3B18A-2514-44E3-9F3B-409C80EFAD18 Q38584194-A95D01C7-70EF-42CB-BA69-78656D266A7A

P2860

Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma.

http://www.wikidata.org/entity/Q37304132

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Experimental and clinical evid ...... ps: Implications for glaucoma.

@en

Experimental and clinical evid ...... ps: Implications for glaucoma.

@nl

type

label

Experimental and clinical evid ...... ps: Implications for glaucoma.

@en

Experimental and clinical evid ...... ps: Implications for glaucoma.

@nl

prefLabel

Experimental and clinical evid ...... ps: Implications for glaucoma.

@en

Experimental and clinical evid ...... ps: Implications for glaucoma.

@nl

P1433

Q37304132-DD5724B5-1ACC-4061-B2A2-4D22731E8C70

P1476

Q37304132-4627E317-B988-48C0-A3C4-E88614C51876

P2093

Q37304132-37AB1CAE-B0DA-409B-8C3F-8C6F9A9BB0F2

Q37304132-55FB4D77-424B-485D-A365-FBA0F8378E4B

Q37304132-68F85831-FA0E-4951-A499-7481086E9F8F

Q37304132-90FC7D58-446B-4D09-A437-59727CAE83D2

Q37304132-944C2161-382E-40E9-AF3A-209363B06280

Q37304132-A18D0F87-8D18-4F37-9B0D-2007D8146DA3

Q37304132-BFA878A4-53B1-4842-88E3-3A4C7043F7D3

Q37304132-D1E8E1A7-1422-4BB6-BD12-02C2AB08A559

Q37304132-DBBE78F9-F449-428E-B769-5ED275FB16D7

Q37304132-FDFF3241-2152-48E6-BCD6-C25255B1BC54

P2860

Q37304132-032825E9-4769-449B-B9E6-ABDAB442FEB1

Q37304132-03DBF29B-3CBC-427E-9718-82A7CBCBCD8E

Q37304132-0E965443-5608-42A7-BD02-0D3E60DEFFB9

Q37304132-21B5E1CA-D185-4286-B7C2-F05975B490B5

Q37304132-287DE4AE-803E-40A0-8E43-E1354D58328C

Q37304132-29A2B79C-46C6-4CC4-AB11-630CB1D746C6

Q37304132-2ADF29EA-DCE1-4D7D-A96C-40420F45775E

Q37304132-2E78BD53-E136-44E0-9D86-23CF282A9E7E

Q37304132-45BDF252-E47B-48D0-9787-BDA30FA50CC1

Q37304132-510953B0-5403-4321-A2B2-0015182EE983

P304

Q37304132-08AB8D75-AB62-44A2-A79D-A504570CE9FD

P31

Q37304132-1DE4E2A4-E9F8-42FB-82E9-CB342F031706

P356

Q37304132-6730159D-A3D2-400D-BADB-6B3E62EB28E5

P407

Q37304132-6A5CBAF4-DEC5-4647-A7C7-F9A964D02D90

P433

Q37304132-69A5EDAB-C33A-4C73-882D-42ECF8C37154

P478

Q37304132-BDFF6087-7332-4F27-8092-C1DE4ACFB186

P50

Q37304132-6C3C20DD-AD8E-4BC6-910C-958DF08DD369

P577

Q37304132-2B80F428-0DC5-4121-AB82-953534DFA70A

P5875

Q37304132-2F354EDA-5A92-4576-9FBC-BBBEBFCA9124

P698

Q37304132-F898AEAB-685C-4041-8703-E1F064F36729

P932

Q37304132-A129FAEF-192B-4956-9481-A36F95672DC0

P356

PNAS.0906678106

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Experimental and clinical evid ...... ps: Implications for glaucoma.

@en

P2093

Alessandro Lambiase

http://www.w3.org/2001/XMLSchema#string

Flavio Mantelli

http://www.w3.org/2001/XMLSchema#string

Gian Luca Manni

http://www.w3.org/2001/XMLSchema#string

Luigi Aloe

http://www.w3.org/2001/XMLSchema#string

Marco Centofanti

http://www.w3.org/2001/XMLSchema#string

Massimo Gilberto Bucci

http://www.w3.org/2001/XMLSchema#string

Sonia Nair Báo

http://www.w3.org/2001/XMLSchema#string

Stefano Bonini

http://www.w3.org/2001/XMLSchema#string

Valieria Colafrancesco

http://www.w3.org/2001/XMLSchema#string

Vincenzo Parisi

http://www.w3.org/2001/XMLSchema#string

P2860

Glaucoma is second leading cause of blindness globally

Role of neurotrophin receptor TrkB in the maturation of rod photoreceptors and establishment of synaptic transmission to the inner retina

Impaired visual function in glaucoma.

Nerve growth factor: structure and function.

Topical treatment with nerve growth factor for corneal neurotrophic ulcers.

Transplants and neurotrophic factors increase regeneration and recovery of function after spinal cord injury.

Retinal ganglion cells and neuroprotection for glaucoma.

Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation.

Glaucoma: ocular Alzheimer's disease?

Acute and long-term synaptic modulation by neurotrophins.

P304

13469-13474

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0906678106

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Rita Levi-Montalcini

P577

2009-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235612310

http://www.w3.org/2001/XMLSchema#string

P698

19805021

http://www.w3.org/2001/XMLSchema#string

P932

2726400

http://www.w3.org/2001/XMLSchema#string